All In Biotech

Drug Trial Radar · NCT06080789

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis

A Phase 2a, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 Administered by Endoscopic Ultrasound-Guided Peripancreatic Injection Plus Standard-of-Care Versus Standard-of-Care Only in Participants With Predicted Severe Acute Pancreatitis

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jun 28, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Panafina, Inc.Industry
Sponsor type
Industry
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis. The main question the study aims to answer is: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis. The study also aims to answer: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis. Study participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only. The study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.

Conditions

  • Acute Pancreatitis

Interventions

  • RABI-767Drug

    125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: Enrollment/Randomization to Day 28 (or hospital discharge, if earlier)
  2. Number of Participants with Serious Adverse EventsTime frame: Enrollment/Randomization to Day 35 Follow-up
  3. Change from Baseline in Clinical Chemistry ParametersTime frame: Baseline to Day 7
  4. Change from Baseline in Hematology ParametersTime frame: Baseline to Day 7
  5. Change from Baseline in Vital SignsTime frame: Baseline to Day 7
  6. Change from Baseline in Pulse Oximetry and Oxygen Delivery MeasurementsTime frame: Baseline to Day 7

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Keck Hospital of USC and LA County Hospital

    Los Angeles, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • University of Florida Health

    Gainesville, Florida · Recruiting

  • Orlando Health

    Orlando, Florida · Recruiting

  • UI Health, University of Illinois Chicago Hospital Health Sciences System

    Chicago, Illinois · Recruiting

  • Indiana University Health University Hospital

    Indianapolis, Indiana · Withdrawn

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire · Recruiting

  • NYU Langone Medical Center

    New York, New York · Recruiting

  • Postgraduate Institute of Medical Education and Research

    Chandigarh, India · Recruiting

  • All India Institute of Medical Sciences

    Delhi, India · Recruiting

  • Govind Ballabh Pant Institute of Postgraduate Medical Education and Research

    New Delhi, India · Recruiting

  • Lisie Hospital

    Kochi, Kerala, India · Recruiting

  • Christian Medical College (CMC) Vellore, Ranipet Campus

    Vellore, TamiNadu, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.